Crinetics Pharmaceuticals Inc.

This study is testing an investigational drug called atumelnant in children aged 1 to 18 with a genetic hormone disorder called congenital adrenal hyperplasia (CAH). The main goals are to see if the drug is safe, if it can help control abnormal hormone levels, and if it allows ch…

This early-stage clinical trial is testing a new drug called CRN09682 for people with advanced neuroendocrine tumors and other solid tumors that have a specific marker (SST2). The main goals are to find a safe and tolerable dose and to see if the drug shows early signs of helping…

This study is testing whether a daily pill called atumelnant can better control hormone levels in adults with classic congenital adrenal hyperplasia (CAH), a rare genetic condition. About 150 participants will receive either atumelnant or a placebo pill for comparison. The main g…

This study aims to learn about the long-term safety and effectiveness of the experimental drug atumelnant (CRN04894) for people with congenital adrenal hyperplasia (CAH), a rare genetic hormone condition. It is open to about 150 people who have already taken this drug in a previo…

This study is testing whether an investigational drug called paltusotine can better control the main symptoms of carcinoid syndrome—flushing and diarrhea—compared to a placebo. It will involve about 141 adults who have carcinoid syndrome due to neuroendocrine tumors. Participants…